Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Serina Therapeutics (SER) Non Operating Income (2018 - 2025)

Historic Non Operating Income for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Serina Therapeutics' Non Operating Income fell 7315.91% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 2280.75%. This contributed to the annual value of $5.8 million for FY2024, which is 3044.77% down from last year.
  • Serina Therapeutics' Non Operating Income amounted to $1.8 million in Q3 2025, which was down 7315.91% from -$897000.0 recorded in Q2 2025.
  • Serina Therapeutics' Non Operating Income's 5-year high stood at $9.0 million during Q2 2024, with a 5-year trough of -$12.7 million in Q1 2024.
  • Over the past 5 years, Serina Therapeutics' median Non Operating Income value was $437000.0 (recorded in 2021), while the average stood at $643263.2.
  • Over the last 5 years, Serina Therapeutics' Non Operating Income had its largest YoY gain of 864000.0% in 2021, and its largest YoY loss of 2710000.0% in 2021.
  • Serina Therapeutics' Non Operating Income (Quarter) stood at -$292000.0 in 2021, then plummeted by 235.27% to -$979000.0 in 2022, then soared by 182.74% to $810000.0 in 2023, then soared by 245.31% to $2.8 million in 2024, then crashed by 35.75% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, -$897000.0 for Q2 2025, and $1.0 million during Q1 2025.